Corcept Therapeutics price target raised to $73.50 from $72 at Ladenburg
The Fly

Corcept Therapeutics price target raised to $73.50 from $72 at Ladenburg

Ladenburg raised the firm’s price target on Corcept Therapeutics (CORT) to $73.50 from $72 and keeps a Buy rating on the shares after the company reported “strong” Q3 revenue and raised 2024 revenue guidance. The firm cites the underlying Korylm business and increased revenue projections for 2024 and 2025 for its increased price target

Don't Miss out on Research Tools:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App